PCV11 Cost-Effectiveness of Intravascular Ultrasound (IVUS) during Drug-Eluting Stent Implantation in Korea

Abstract

Objectives: Coronary atherosclerotic heart (CAD) is the world's biggest killers during the past decade, and has become a global public health problem that seriously threatens human health. However, annual economic burden of CAD in China is not well studied. This study aims to evaluate the annual economic burden including direct and indirect cost of CAD from societal perspective in China. Methods: A disease burden model was developed to calculate the number of treated CAD patients stratified by different subtypes and the economic burden on CAD patients in China. The data for model inputs were retrieved from literature review, real word data from sites and in-depth interviews with clinical experts. Key clinical expert confirmed the validity of the data. Two -step model method and human capital method were used to assess the economic burden of CAD. Results: Total 14.60 million CAD patients received treatment in 2018, including 12.34 million out-patients and 3.73 million inpatients. The average total annual cost was CNY 228.59 billion (15662 per treated patient). The majority (68.5%) is the direct medical cost, followed by the indirect cost accounting for 22%. In terms of direct medical costs related to hospital visits, outpatient's cost was lower than inpatient's (CNY 48.30 vs CNY 82.10 billion), and the burden of patients with myocardial infarction (MI) is the highest and the patients with stable angina pectoris had lightest burden (CNY 68.28 and 13.24 billion). Outpatient's cost was higher than inpatient's in terms of indirect cost (CNY 40.36 vs CNY10.61 billion), and the patients with MI and unstable angina had higher burden. Conclusions: The CAD was a chronic disease with a large number of patients, bringing greater economic risks to patients and society. Chronic disease management and lifestyle intervention need to be strengthened to reduce the incidence of CAD.